Serotonin is involved in disorders of the central nervous system; thus, specific 5-HT 6 receptor antagonists have therapeutic potential. Nevertheless, preclinical tests showed that Ro 65-7199 caused hepatic steatosis. Here, we investigated the hepatic effects of Ro 65-7199 and Ro 66-0074 using toxicogenomics. The profiles obtained after exposure of rats to both compounds clearly show that two pharmacologically closely related compounds with different toxicological profiles can be distinguished based on gene expression profiles. Moreover, side effects can be detected earlier with toxicogenomics than with conventional end points. A possible link between the sterol metabolic pathway, the induction of CYP2B, and the hepatic fat accumulation was also established. Summarizing, gene expression profiles allow both compounds to be distinguished according to their toxicity and provide mechanistic insights. The results clearly show the power of toxicogenomics as a tool for obtaining characteristic fingerprints at early time-points and for generating mechanistic hypotheses.
INTRODUCTION
Serotonin (5-hydroxytryptamine, 5-HT) has been shown to be involved in the pathogenesis of a number of disorders in the central nervous system. 1 This neurotransmitter binds to the serotonin receptor family, which is a member of the larger family of G-protein-coupled receptors. 2 Several serotonin receptors (5-HT receptors) have been cloned and characterized, including the 5-HT 6 receptor. 3 Northern blot analysis has shown that the 5-HT 6 receptor is expressed mainly in brain, with very weak to no expression in the periphery. 3, 4 This receptor appears to be involved in certain anxiety disorders, and functional studies have demonstrated that blocking the receptor enhances acetylcholine neurotransmission in the rat brain. 5, 6 Furthermore, experiments performed with antisense oligonucleotides and with specific 5-HT 6 receptor antagonists showed that blocking this receptor type produced an increase in the retention of learning in rats. 7 Thus, its functional characteristics in the behavioral studies have shown that the 5-HT 6 receptor is a potential target for the treatment of memory deficit as in patients with Alzheimer's disease. Moreover, due to the specific localization of the receptor in the brain, fewer side effects are expected with specific 5-HT 6 receptor antagonists than with other commonly used therapies such as acetylcholinesterase inhibitors or muscarinic agonists. One of the compounds selected as a possible clinical candidate was 4-amino-N-(6-bromo-1H-indol-4-yl)-benzenesulfonamide (Ro 65-7199). Unpublished toxicity data have shown that the compound caused hepatic lipid accumulation in rats treated with high doses. The lack of expression of 5-HT 6 receptor in the liver provided a strong argument against toxicity due to exaggerated pharmacological activity. In addition, another 5-HT 6 antagonist, 4-(2-bromo-6-pyrrolidin-1-yl-pyridine-4-sulfonyl)-phenylamine (Ro 66-0074), did not cause hepatic steatosis. Ro 66-0074 is closely related to Ro 65-7199 since it displays similar pharmacological activity (Figure 1) .
In the present study we sought to further investigate Ro 65-7199-induced hepatotoxicity, which in this case refers specifically to hepatic microvesicular steatosis, using a toxicogenomics approach. In order to gain insight into the possible molecular mechanisms underlying the described hepatic findings, the effect of acute (single dose) and subchronic (1 week, daily dosing) administration of Ro 65-7199 on hepatic gene expression was assessed using Affymetrix GeneChips. In addition, the effect of acute exposure to Ro 66-0074 was also analyzed. Thus, we have generated gene expression profiles of the livers of rats treated with both 5-HT 6 receptor antagonists and evaluated the differences regarding the modulation of gene expression.
With this work we also intend to provide a set of data supporting toxicogenomics as an approach to address toxicological issues and liability. [8] [9] [10] [11] [12] Several investigators from academia and industry have vastly speculated upon the usefulness of gene expression analysis in toxicology, but relatively few studies describing the characterization of already well-known hepatotoxins using transcript profiling have been published. [13] [14] [15] 
RESULTS

Clinical Chemistry and Histopathology
As seen in previous studies, there was a dose-related increase in fatty change in the liver. Fatty change was assessed microscopically for each animal using a semiquantitative grading ranging from 0 (no finding) to 5 (severe finding).
Group severity values were obtained by averaging the gradings of all animals in the group. After 1 week of administration of Ro 65-7199 (Table 1, Figure 2 ), the mean severity increased from 1.0 in the low-dose group to 1.8 in the mid-dose group to 2.8 in the high-dose group. Regarding the incidence of the findings, only one out of four animals in the time-matched control group showed fatty change, while all rats treated during 7 days with Ro 65-7199 were affected. In addition, hepatocellular vacuolation affecting all rats in the high-dose group (mean severity 2.6) was noted. Hepatocellular vacuolation was characterized by multiple small discrete periacinar vacuoles that sometimes coalesced to form larger ones and stained positive for lipids (microsteatosis).
A single administration of Ro 65-7199 at 400 mg/kg resulted in an increase in the severity of fatty change (mean grade 2.2) at 24 h with respect to the controls (mean grade 1.2) and with Ro 66-0074 at 400 mg/kg (mean grade 1.4). This change was correlated with hepatocellular vacuolation (microsteatosis). In addition, rats treated with Ro 65-7199 showed a slight increase in the incidence (three out of five) and grade (1.7) of mitosis.
There were only negligible differences in the livers of rats 6 h after treatment with Ro 65-7199 or Ro 66-0074 when compared with their respective controls.
Hepatic lipid accumulation after 7 days of Ro 65-7199 treatment (400 mg/kg/day) was accompanied by a slight decrease in serum cholesterol and triglycerides, as well as by a slight increase in serum 5 0 -nucleotidase (5-ND) and g-glutathione transferase (g-GT). The latter reached detectable levels only in the animals treated with the high dose of Ro 65-7199 during 7 days and was under the detection limit for all other groups (data not shown). Liver transaminases (aspartate aminotransferase (AST) and alanine aminotransferse (ALT)) and lactate dehydrogenase (LDH), typical markers of hepatic toxicity, were decreased in most treatment groups rather than increased (Table 2) . Serum triglycerides showed a dose-dependent decrease after subchronic treatment, but this finding did not reach statistical significance. Conversely, a transient, significant increase in serum triglycerides was seen after acute treatment with Ro 65-7199 at 24 h. Total hepatic lipid content was also increased at high doses of Ro 65-7199 after 7 days or 24 h of treatment but this increase did not show dose dependence. In addition, an increase in hepatic lipid content was also observed with Ro 66-0074 after 24 h of treatment (Table 2) .
Gene Expression Analysis
Analysis of the gene expression data showed a relatively small number of genes modulated by either compound. It was interesting to note that even the livers of animals treated during 7 days with the high dose of Ro 65-7199 and Effect of 5-HT6 receptor antagonists on the rat liver L Suter et al displaying steatosis showed modulation (two-fold change, Pr0.05, signal Z100) of only 85 out of 8800 probe sets represented on the array. From these 85 probe sets, only 30 were induced while the rest were repressed. Approximately half of the genes upregulated by Ro 65-7199 after 7 days of treatment at 400 mg/kg showed induction at the lower dose levels (30 and 100 mg/kg) in a dose-dependant manner. Some of the genes induced by subchronic treatment with Ro 65-7199 were also upregulated following acute treatment at 6 h (approximately one-third of the probe sets) and at 24 h (more than two-thirds of the probe sets). Very few genes were regulated by the high dose (400 mg/kg) of the nonhepatotoxic compound Ro 66-0074 at 6 or 24 h after a single administration. The expression levels of the genes used for the cluster analysis depicted in Figure 3 are listed in Table 3 . In addition, expression levels of selected genes discussed further due to mechanistic relevance are included in Table 4 . A complete list of all gene expression values can be found at http://www.roche.com/ science-download.htm. 
Findings are expressed as average grading for the group and its incidence (number of animals affected/number of animals evaluated). Grading ranges from 0 (no finding) to 5 (severe findings).
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Further analysis using hierarchical clustering (Figure 3a and b) showed a characteristic pattern for Ro 65-7199 across doses and time points that allowed its differentiation from Ro 66-0074. Notably, genes modulated after subchronic treatment with Ro 65-7199 could be employed to differentiate both compounds after acute administration. Among the genes induced by Ro 65-7199 were several probe sets specific to cytochromes P450 CYP2B1/2 and CYP3A1, while the repressed genes included ornithine aminotransferase (AA893325), alcohol sulfotransferase (D14987), hepatocyte nuclear factor 3 gamma (HNF-3g, AB017044), and serine dehydratase (J03863). In addition, some genes related to lipid and cholesterol homeostasis, such as hydroxymethylglutaryl-coA synthase (HMGCoA Synthase, X52625) and CYP7B1 (U36992), were deregulated by the treatment with the steatotic compound Ro 65-7199. Although the extent of the change did not always reach the arbitrarily set threshold of two-fold, some genes appeared consistently regulated and possibly bear biological relevance. In particular, senescence marker protein (D31662), hepatocyte nuclear factor 1-alpha (HNF-1a, J03170) and the epidermal and the hepatic forms of fatty acid binding protein (S69874 and V01235) were significantly repressed, while malic enzyme (AI171506) and epoxide hydrolase (M26125) were induced (Table 4) .
Results obtained using the Affymetrix arrays confirmed that expression levels of the pharmacological target of both test compounds, the 5-HT 6 receptor (S62043), is not detectable in the liver either in controls or treated animals.
RT-PCR
The cluster analysis and the data depicted in Figure 3 and Table 3 show several genes that allow the discrimination of both compounds after acute administration. A group of genes induced by Ro 65-7199 but not by Ro 66-0074 was chosen for confirmation of the gene expression results using RT-PCR monitored by Sybr-green. Generally, the induction obtained with the microarrays could be confirmed by RT-PCR, although the fold changes obtained with both platforms often differed. This is particularly true for the cytochrome P450 CYP2B, where induction could be clearly confirmed using two different primer pairs. Nevertheless, it needs to be pointed out that the transcriptional induction of this gene as assessed by RT-PCR shows some inconsistencies.
In particular, the induction of CYP2B2 after 7 days of repeated treatment with Ro 65-7199 (400 mg/kg/day) resulted in a weaker induction, as expected from the dose dependence observed using microarrays. This weaker induction might be due to a technical artifact, as indicated by the dose-dependent induction detected with the primer pair directed to a different portion of the sequence (CYP2B, exon 9). For the weakly expressed glutathione reductase, the slight induction (2.1-fold at the high dose after 7 days) detected with the microarray after 7 days of Ro-65-7199 administration could not be confirmed ( Table 5 ). The results obtained by PCR analysis show that the expression levels of these genes after acute administration (6 and 24 h) would suffice to differentiate both compounds, even though the genes were selected based on the results obtained after subchronic exposures to Ro 65-7199.
Western Blots
Among the upregulated probe sets, several were specific to cytochrome P450. In particular, an induction of CYP2B was detected by several probe sets and confirmed by RT-PCR. Western blots were performed using specific antibodies against the CYP2B family in order to evaluate if the clear induction of messenger RNA also led to an increase in the hepatic protein levels. In addition, Western blots using an antibody against CYP2C11, whose mRNA was not induced by the treatment, was also assessed (Figure 4) . The results of the protein levels of both cytochromes closely paralleled the amounts of mRNA at 24 h and at 7 days after Ro 65-7199 treatment. However, the induction of CYP2B could not be detected 6 h after administration of Ro 65-7199, in spite of the increased levels of messenger RNA ( Figure 5 ). As expected, none of the treatments resulted in an induction of CYP2C11.
DISCUSSION
We investigated the effects of two 5-HT 6 receptor antagonists on the gene expression patterns in the liver of male rats. Both compounds share the same pharmacological target, but results from prior unpublished studies uncovered strikingly different toxicity profiles: while Ro 65-7199 is known to cause hepatic steatosis, Ro 66-0074 has never been shown to induce any hepatotoxicity. In the present study, we have reproduced the findings of the above-mentioned unpublished toxicology studies with respect to the hepatotoxicity (steatosis) caused by Ro 65-7199 after subchronic exposure. Moreover, we have gained insight into the underlying mechanisms leading to or at least indicative of such toxic events. Gene expression results obtained using Affymetrix GeneChips confirmed the lack of expression of the 5-HT 6 receptor in the liver of control and treated animals. 3, 4 Since the pharmacological target is absent from hepatic tissue, it is expected that these compounds will cause few, if any direct pharmacological reactions in the liver. Indeed, this was confirmed by the relatively small number of genes that appeared modulated even after treatment with a high dose of the toxic compound Ro 65-7199 during 7 consecutive days. In previous toxicogenomics studies using microarrays evaluating a similar number of genes, the investigated model hepatotoxins usually affected hundreds of genes, especially when administered at high doses. 14, 16 This is due to the direct effect of the compounds on the liver, as well as to indirect effects due to widespread hepatocellular damage. In the present study, the compounds did not elicit a pharmacological effect in the liver, not even at the high doses selected for toxicity studies, which probably surpass the expected human exposure. Thus, the changes in gene expression may be chiefly attributed to the mechanisms leading to or caused by the specific toxic event triggered by Ro 65-7199 or to unspecific signals. The gene expression profiles obtained after exposure to both compounds clearly show that they can be distinguished based on their effect on gene expression patterns in the liver after acute exposure. As shown in the cluster analysis ( Figure 3 ), this was true at 6 and 24 h after single administration, while conventional toxicology end points were unspecific. These results demonstrate that two very closely related compounds can be differentiated using toxicogenomics. Moreover, potential side effects can be detected earlier with gene expression analysis than with conventional toxicology measurements. This finding is vital in order to further assess the usefulness of toxicogenomics approaches to improve the process of detecting the toxic potential of compounds quicker and more accurately than with conventional toxicity studies. In addition, gene expression results after subchronic exposure to Ro 65-7199 showed that the modulation of gene expression also reflects the histological findings. As can be extracted from Table 4 , a group of the modulated genes shows a dose dependence in the intensity of the modulation that parallels the severity of the histological findings.
From a mechanistic point of view, analysis of complex gene expression profiles has allowed us to identify genes that may be associated with the toxic event under investigation. In this case, it was surprising that some cytochromes P450 (CYP2B and CYP3A1) were consistently induced by Ro 65-7199. In particular, the induction of CYP2B2 is a gene expression change that may be associated with the toxicity elicited by Ro 65-7199 ( Figure 5 ). Our results show a dose-dependent induction of CYP2B2 mRNA after 7 days of treatment as well as at 6 and 24 h after a single dose administration of Ro 65-7199. The nonhepatotoxic Ro 66-0074 did not cause the induction of this gene. Moreover, the increase in mRNA was paralleled by an increase in immunoreactive protein as detected by Western blot analysis at 24 h and at 7 days. The lack of increase in the protein content at 6 h is due to the time lag between transcription and translation processes described elsewhere. 16, 17 This induction is specific for certain cytochromes Figure 3 Hierarchical clustering using 85 probe sets significantly (two-fold change, P-value r0.05) regulated after 7 days of treatment with Ro 65-7199 (400 mg/kg/day). Cluster analysis (either by groups or by genes) was performed using a correlation algorithm to calculate the distance function and the average linkage method. Table 3 .
Effect of 5-HT6 receptor antagonists on the rat liver L Suter et al Table 3 Gene expression values of genes that are significantly modulated by 400 mg/kg/day of Ro 65-7199 during 7 days, as depicted in the heat map in Figure 3b Affymetrix probe set ID Acc. no. P450, such as CYP2B, CYP2C6, and CYP3A1, while no induction was observed for CYP2C11 or other cytochromes such as the CYP1A and the CYP4A families. The CYP2B family, and to a lesser extent CYP3A1 and CYP2C6, is known to be inducible by phenobarbital, a rodent-specific nongenotoxic carcinogen with so far little relevance to human hepatotoxicity. [18] [19] [20] [21] Several probe sets detected the induction of genes from the CYP2B family, including CYP2B2 (exons 1 and 9) and CYP2B15, which are all inducible by phenobarbital. 22, 23 In the present study, a novel link between the induction of CYP2B2 and other phenobarbital-inducible cytochromes P450 in the rat, and the potentially human-relevant microvesicular steatosis could be established. Whether the induction of this gene is a cause or an effect of the underlying mechanisms or a possible adaptive response is not clear. In any case, this phenobarbital-like response occurs prior to the appearance of major histological findings, already at the low dose (30 mg/kg, 7 days) administered subchronically and at the earliest tested time point (400 mg/kg, 6 h) after acute exposure.
At this time, it is difficult to define the mechanistic link between the observed modulation of gene expression and the subsequent liver damage, but the obtained results allow for some hypothesis generation. It has been previously published that the effect of phenobarbital on CYP2B induction is gender dependent and that this induction is partially inhibited either at the transcriptional or at the post-translational level in females and in younger animals. 24 In addition, Kawamoto et al 25 have shown that estrogens are activators of the constitutive androstane receptor (CAR), a nuclear receptor that induces the transcription of the CYP2B family after exposure to xenobiotics such as phenobarbital. Thus, there is a link between gender and CYP2B induction, as there is a link between steatosis and gender, women being more prone to hepatic steatosis than men. 26 However, the gender-specific response was not addressed in this study, since only male animals were analyzed in order to minimize variability due to asynchrony in the estrus cycles. Additionally, it has recently been published that an endogenous molecule related to cholesterol homeostasis interacts with the phenobarbital-response enhancer sequences of some phenobarbital-induced cytopchromes P450, 27 and induction of rat CYP2B was observed after inhibition of cholesterol synthesis. 28 These reports, taken together with the observed induction of CYPs and reduction in serum cholesterol, suggest a possible causal relation between an impairment of the sterol metabolic pathway (possibly an inhibition of the cholesterol synthesis), the induction of CYP2B, and the fat accumulation in the hepatocytes. Additional results supporting the relationship of cholesterol homeostasis and induction of CYP2B caused by CAR activation as a mechanism of hepatic defense toward bile acid toxicity have been published. 29, 30 These reports underline the complex relationships between bile acid, cholesterol, and lipid homeostasis and activation of nuclear receptors, including CAR. 30 Furthermore, our results show a significant decrease in circulating cholesterol and transcriptional regulation of enzymes related to the sterol # Genebank acc. no., gene symbol, and short name: extracted and adapted from Affymetrix descriptions (www.affymetrix.com). NA: not available. Max. signal: the average intensity of the treatment group with the highest signal. This parameter indicates whether a gene is high or low expressed. Probe sets with intensity lower than 100 are considered to be nondetectable. FChg: induction/repression expressed as fold change with respect to the time-matched control. P-value: significance level obtained from a t-test. 
metabolic pathway (downregulation of cytoplasmic HMGCoA synthase and CYP7B1), and of genes coding for proteins involved in cellular lipid homeostasis (ie malic enzyme and epoxide hydrolase). Thus, the link between hepatic lipid accumulation and CYP2B induction probably occurs due to the cross talk between several nuclear receptors and the impairement of the cholesterol Table 5 Results of QRT-PCR analysis of a subset of genes and comparison with the results obtained using the Affymetrix platform Description Genebank acc. no. Effect of 5-HT6 receptor antagonists on the rat liver L Suter et al synthesis. 31 In fact the slight, yet significant transcriptional regulation of aryl hydrocarbon receptor (AhR) and hepatic nuclear factors (HNF-1a and HNF-3g) might be additional indicators of such a mechanism.
Alternatively, it can also be argued that the induction of CYPs by the steatotic 5-HT 6 receptor antagonist Ro65-7199 is a reaction to fatty change in the liver rather than part of its cause. However, the fact that the upregulation of CYP2B occurs prior to the onset of steatosis and that an excess of fat storage in the liver is known to decrease protein concentration and enzymatic activities of several CYPs 32 make this unlikely. In any case, there is no evidence that the induced CYP2B family is involved in the metabolism of Ro 65-7199. Metabolic studies demonstrated that the main metabolite of this compound is an N-glucoronide, while phase I metabolism plays a minor role in the rat. However, studies performed with human metabolizing enzymes showed an inhibition of human CYP3A4 by Ro 65-7199 (data not shown).
Another finding that might bear mechanistic relevance to the steatosis caused by Ro 65-7199 is the transcriptional regulation of several proteins involved in cellular lipid homeostasis. Some of these mRNAs were sometimes only slightly regulated (50% up-or downregulation) by Ro 65-7199. Among these, an upregulation of microsomal epoxide hydrolase (M26125) and a downregulation of the cutaneous and hepatic isoforms of fatty acid-binding protein (S69874, V01235) were observed. The latter downregulation could have been a consequence of reduced levels of HNF-1a observed. Indeed, the dose-dependent downregulation of HNF-1a, followed by lower levels of FABP are in line with previous reports describing decreased expression of the hepatic form of FABP in null-HNF1a mice displaying fat accumulation in the liver. 33 In our model, this gene expression finding seems to be a late manifestation of toxicity, since it only becomes apparent after subchronic administration of the high dose of Ro 65-7199.
Summarizing, in this study, toxicogenomics allowed an in-depth analysis of dose-(several doses during 7 consecutive days) and time-(6 and 24 h and 7 days) related gene expression events related to the steatotic compound Ro 65-7199. Moreover, the inclusion of animals treated acutely with the nontoxic Ro 66-0074 enabled us to define groups of genes that allowed differentiation of two structurally and pharmacologically closely related compounds with different toxicological profiles. The gene expression profiles obtained not only allowed us to clearly distinguish both compounds according to their toxicity before hepatotoxicity was apparent by conventional end points, but also allowed us to identify some genes that might be directly or indirectly involved in the underlying mechanisms of toxicity. The results presented in this paper clearly show the power of toxicogenomics as a tool for generating characteristic fingerprints at early time-points as well as a tool to generate knowledge-based mechanistic hypotheses. Once validated, toxicogenomics could significantly shorten the duration of pilot toxicity studies, thus reducing the amount of compound needed, and limiting the cost. It will also indicate causes leading to the observed liabilities and provide targets amenable to mechanistic in vitro screening tools.
MATERIALS AND METHODS
Animals and Treatment
This study was designed according to previous unpublished routine toxicity studies. All animals received humane care as specified by Swiss law and in accordance with the 'Guide for the care and use of laboratory animals' published by the NIH. Male Wistar rats were purchased from BRL (Füll-ingsdorf, Switzerland) and housed individually. For the acute exposures, rats (five males/group) were dosed orally (gavage) once with a high dose (400 mg/kg) of Ro 65-7199 or Ro 66-0074 and killed by CO 2 asphyxiation 6 or 24 h after dosing. For the subchronic exposures, animals were dosed orally (gavage) for 7 days with Ro 65-7199 at 30, 100, or 400 mg/kg/day and killed 24 h after the last administration. For each time point, a time-matched control group (five animals/group) was dosed with the vehicle (distilled water). The livers of all animals were excised immediately after killing and placed either in RNALater (Ambion, TX, USA) and stored at À201C for gene expression analysis or in liquid nitrogen and kept at À801C for subsequent protein (Western blot) and lipid content measurement. Blood samples for clinical chemistry were obtained shortly before killing. Additional liver samples obtained during necropsy were fixed for routine histopathological evaluation.
Clinical Pathology and Histopathology
Lipid levels and the enzymatic activities of AST, ALT, LDH, g-GT, and 5-ND were measured in serum samples. Automated analysis was performed using commercially available test kits (Roche Diagnostics, Mannheim, Germany) on a Cobas Fara autoanalyzer (Roche, Rotkreuz, Switzerland). Lipids were extracted from liver homogenates as described by Freneaux et al, 34 and the levels of triglycerides, phospholipids, and total lipids were measured on a Cobas Fara autoanalyzer. For histological evaluation, samples from the liver (caudate process, left lateral lobe) were fixed in 10% buffered formalin for at least 24 h, and then embedded in Paraplast. Sections approximately 2-3 mm thick were cut and stained with hematoxylin-eosin and with Fat-Red-O-for the visualization of lipids.
Gene Expression Analysis
Total RNA was extracted from the livers of all animals following standard laboratory protocols. Briefly, total RNA was extracted from approximately 150 mg of liver tissue using RNAzol (Tel-Tex Inc., TX, USA) and a commercially available kit (Bio 101, CA, USA). Total RNA was purified using RNeasy columns (Qiagen, Hilden, Germany) before quantification and assessment of ribosomal RNA integrity on agarose gels.
GeneChip Analysis Double-stranded cDNA was synthesized from 20 mg of total RNA using a commercially available cDNA-synthesis kit with an oligo dT-T7 promoter primer (Roche Molecular Effect of 5-HT6 receptor antagonists on the rat liver L Suter et al Biochemicals, Mannheim, Germany). The obtained cDNA was used as a template for in vitro transcription using the Megascript kit purchased from Ambion (TX, USA) supplemented with biotinylated nucleotides (Bio-11-CTP and Bio-16-UTP) provided by Roche Molecular Biochemicals (Mannheim, Germany). Fragmented in vitro transcripts (cRNAs) were hybridized overnight onto commercially available rat microarrays containing 8799 rat-specific probe sets (RG-U34A, Affymetrix, CA, USA). The hybridized samples were stained with streptavidin-R-phycoerythrin (SAPE, Molecular Probes, CA, USA) and the signal amplified using a biotinylated goat anti-streptavidin antibody (Vector Laboratories, CA, USA) followed by a final staining with SAPE. Washing, staining, and amplification were carried out in a fluidics station provided by Affymetrix. Microarrays were scanned in an Affymetrix GeneArray scanner (gain setting: 18 000). The obtained image files were analyzed with the software Microarray Suite 5.0 (Affymetrix), while pairwise comparisons between treated and control group and statistical analysis were performed with in-house developed software (RACE-A, Roche, Basel, Switzerland).
RT-PCR
After digestion of genomic DNA using 'Absolutely RNA'-Miniprep kit (Stratagene Europe, Amsterdam, Netherlands), 10 mg of total RNA was used for synthesis of single-stranded cDNA using a commercially available cDNA-synthesis kit with an oligo dT-T7 promoter primer (Superscript II, Gibco BRL Paisley, Scotland). The obtained cDNA was used as a template for several PCR reactions using appropriate specific primers (Table 6 ) and the SYBR Green PCR Master Mix (Applied Biosystems, Rotkreuz, Switzerland). The production of double-stranded amplification products binding SYBR Green was measured using the ABI-PRISM 7700 sequence detection system (Applied Biosystems). The specificity of the amplified products was assessed by recording the melting curve and by evaluation of the product (size and number of bands) on agarose gels.
Western Blot Analysis
Protein amount in hepatic extracts was quantified using Bio Rad protein assay. 10 mg of total liver protein was denatured in load buffer and separated using SDS-PAGE on a Novex gradient gel (4-20% Tris-glycine, Invitrogen, Basel, Switzerland). After migration, proteins were transferred onto nitrocellulose membranes. Effectiveness of the transfer was assessed by staining the nitrocellulose membrane with Ponceau S red and by staining the gels with Simply Blue Safestain. Membranes were incubated with a specific first antibody (either anti-cytochrome P450 2B1 or anti-cytochrome P450 2C11, raised in goat, purchased at GenTest, Massachusetts, USA) diluted 1 : 1000. Incubation with the second antibody (donkey anti-sheep/goat immunoglobulin horseradish peroxidase conjugated, from Chemikon), diluted 1 : 1000, was subsequently performed under the same incubation conditions. Chemoluminiscence was quantified by densitometry in a Multimage Light Cabinet (Alpha Inotech Corporation, San Leandro, CA, USA) using Table 6 Sequences of the primers used for QRT-PCR Description Genebank acc. no. 
Statistical Data Analysis
All data are typically expressed as mean values with their respective SD. For each measured parameter, the statistically significant differences with respect to the controls were calculated using the two-tailed, unpaired Student's t-test (Pr0.05). For the evaluation of gene expression data using microarrays, output files from the Affymetrix software (MAS 5.0) were further analyzed using in-house developed analysis tools (RACE-A, Roche, Basle, Switzerland). The expression level for each gene is expressed as the mean fluorescence intensity (average difference) and SD of five replicates after Nalimov outlier removal (99% confidence).
Cluster analysis was performed using the correlation function to determine the distance matrix and the average linkage method. Gene expression measured by RT-PCR was evaluated using mean CT values of triplicates, normalized against the CT values for the housekeeping gene GAPDH.
Results are expressed as mean fold changes with respect to the time-matched control group. The threshold for gene induction considered relevant was usually set as 100% up-or downregulation (2-or 0.5-fold change). Protein levels evaluated by Western blots were measured semiquantitatively by densitometry and are expressed in arbitrary units; the values are given as the mean of two representative animals per dose group.
